Quick

자주찾는 메뉴

산학‧연구

 

Benefit and risk of prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with chronic kidney d

개제 일
2022-06-08
주 저자
공동 저자
장양수: 분당차병원 내과
학술지 명
Atherosclerosis
인용 지수
5.162

Benefit and risk of prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with chronic kidney disease: A nationwide cohort study

 

Choongki Kim, Dong-Woo Choi, Seung-Jun Lee, Yongsung Suh, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Eun-Cheol Park, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong

Atherosclerosis, [Online ahead of print], doi: 10.1016/j.atherosclerosis.2022.05.019.

ABSTRACT

Background and aims: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent in patients with chronic kidney disease (CKD) is not clearly established. This study purposed to compare clinical outcomes of patients with 6-12 (standard) versus 12-24 months (prolonged) DAPT according to CKD.

Methods: Using a nationwide, claim-based database, we retrospectively evaluated association between DAPT duration and clinical outcomes including death, composite ischemic event, and composite bleeding event between 1 and 3 years after PCI. CKD was defined as estimated glomerular filtration rate

Results: In patients with CKD, prolonged DAPT was associated with a lower risk of all-cause death (HR 0.85, 95% CI 0.76-0.95) and composite ischemic events (HR 0.87, 95% CI 0.78-0.96) and a higher risk of composite bleeding events (HR 1.18, 95% CI 1.02-1.37). Benefit of prolonged DAPT on reducing composite ischemic event increased significantly in patients with worsened renal dysfunction (pinteraction = 0.02) while there was no significant interaction between its bleeding risk and renal dysfunction (pinteraction = 0.22).

Conclusions: While standard DAPT would be recommended in patients with normal renal function, tailored decision for DAPT duration would be considered in those with CKD to balance between ischemic and bleeding risks.

Keywords: Chronic kidney disease; Drug-eluting stents; Dual antiplatelet therapy; Percutaneous coronary intervention.

- PMID: 35714431

- Fulltext: https://www.sciencedirect.com/science/article/pii/S0021915022002726?via%3Dihub